MIM
TRML

Monashee Investment Management’s Tourmaline Bio TRML Stock Holding History

Monashee Investment Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,500
Closed -$367K – 369
2021
Q2 		$367K Buy
+2,500
New +$383K 0.04% 247

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Monashee Investment Management's TRML Position: Q3 2021 in Review

Monashee Investment Management sold out of Tourmaline Bio (TRML) in Q3 2021, closing a stake of 2,500 shares — an estimated $367K sold.

Monashee Investment Management first reported a position in TRML in Q2 2021 and held it in 1 quarter. The position peaked at $367K in Q2 2021. 48 funds tracked by Wall St. Rank hold TRML as of Q3 2021.

  • Monashee Investment Management reported no remaining Tourmaline Bio position as of Q3 2021 after selling out during the quarter.
  • Monashee Investment Management sold 2,500 Tourmaline Bio shares in Q3 2021, an estimated $367K.
  • Monashee Investment Management first reported a position in Tourmaline Bio in Q2 2021 and held it in 1 quarter.
  • Monashee Investment Management's Tourmaline Bio position peaked at $367K in Q2 2021.
  • 48 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2021.

Based on Monashee Investment Management's 13F filing for Q3 2021, filed 9 Nov 2021.